PHATHOM PHARMACEUTICALS, INC. (PHAT) Operating Margin
- Operating margin · 12 months: Value -16.96%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -16.96% | Operating income / revenue. Period ending 2026-06-30. $-40.64M ÷ $239.66M × 100 ≈ -16.96% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -40.64M USD | Operating Income (Loss) |
| Revenue | 239.66M USD | |
| Cost of products and services | (m) | |
| Research and development | 30.11M USD | Research and Development Expense |
| Selling, general and administration | 209.27M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-40.64M | $239.66M | (m) | $30.11M | $209.27M | -16.96% |
| 2026-03-31 | $-96.60M | $204.89M | (m) | $31.37M | $239.25M | -47.15% |
| 2025-12-31 | $-159.99M | $175.11M | (m) | $32.78M | $279.72M | -91.36% |
| 2025-09-30 | $-213.47M | $147.19M | (m) | $33.87M | $308.03M | -145.03% |
| 2025-06-30 | $-269.00M | $114.04M | (m) | $35.54M | $332.57M | -235.88% |
| 2025-03-31 | $-286.38M | $81.86M | (m) | $33.84M | $323.13M | -349.84% |
| 2024-12-31 | $-277.47M | $55.25M | (m) | $34.08M | $290.66M | -502.18% |
| 2024-09-30 | $-287.93M | $26.27M | (m) | $38.89M | $270.98M | -1096.02% |
| 2024-06-30 | $-252.79M | $9.92M | (m) | $42.46M | $218.27M | -2548.78% |
| 2024-03-31 | $-207.19M | $2.59M | (m) | $47.85M | $161.34M | -7987.24% |
| 2023-12-31 | $-167.31M | $682.00K | (m) | $49.90M | $117.93M | -24532.55% |
| 2023-09-30 | $-144.08M | (m) | (m) | $52.45M | (m) | (m) |
| 2023-06-30 | $-150.95M | (m) | (m) | $59.21M | (m) | (m) |
| 2023-03-31 | $-164.61M | (m) | (m) | $65.26M | (m) | (m) |
| 2022-12-31 | $-172.44M | (m) | (m) | $71.44M | (m) | (m) |
| 2022-09-30 | $-158.84M | (m) | (m) | $69.05M | (m) | (m) |
| 2022-06-30 | $-149.45M | (m) | (m) | $66.64M | (m) | (m) |
| 2022-03-31 | $-139.40M | (m) | (m) | $69.42M | (m) | (m) |
| 2021-12-31 | $-135.08M | (m) | (m) | $72.34M | (m) | (m) |
| 2021-09-30 | $-154.48M | (m) | (m) | $100.44M | (m) | (m) |
| 2021-06-30 | $-154.17M | (m) | (m) | $109.60M | (m) | (m) |
| 2021-03-31 | $-138.87M | (m) | (m) | $102.86M | (m) | (m) |
| 2020-12-31 | $-125.67M | (m) | (m) | $98.15M | (m) | (m) |
| 2020-09-30 | $-88.92M | (m) | (m) | $69.20M | (m) | (m) |
| 2020-06-30 | $-62.37M | (m) | (m) | $47.90M | (m) | (m) |
| 2020-03-31 | $-125.36M | (m) | (m) | $35.81M | (m) | (m) |
| 2019-12-31 | $-106.22M | (m) | (m) | $20.37M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-84.96M | (m) | (m) | $3.22M | (m) | (m) |
| 2019-03-31 | $-2.20M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-1.23M | (m) | (m) | $20.00K | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |